LOS ANGELES, Dec. 01, 2025 (GLOBE NEWSWIRE) — Raven Capital (“Raven”), an alternative investment firm specializing in asset-based, non-sponsor private credit, today announced that Brian Lanktree has been named Senior Managing Director and Head of Capital Solutions. With more than two decades of global investment experience, he will join the firm and assume this new […]

(CNSX:MAXX),(CNSX:MAXX.CN),(NASDAQ:MSFT),(NASDAQ:AAPL),(NASDAQ:NVDA),(NASDAQ:GOOG),(PinkSheets:MAXXF), This article has been disseminated on behalf of MAX Power Mining Corp. and may include a paid advertisement. AUSTIN, Texas, Dec. 01, 2025 (GLOBE NEWSWIRE) — MiningNewsWire Editorial Coverage: Global electricity demand is entering a historic inflection point. The International Energy Agency (IEA) now forecasts that worldwide data center electricity consumption will nearly double

(NASDAQ:BCDA), SUNNYVALE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) — BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces it will participate at the CSI Focus Devices in Heart Failure this week in Frankfurt, Germany. BioCardia's President and Chief Executive Officer, Peter Altman,

(NASDAQ:SINT), Milestone enables immediate production of SiN/PEEK custom devices SALT LAKE CITY, Utah, Dec. 01, 2025 (GLOBE NEWSWIRE) — SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company, today announced that it has signed a supply agreement with Evonik Corporation (“EVONIK”), a global leader in highâ€'performance polymers, to manufacture

(NASDAQ:PLRX), SOUTH SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the Piper Sandler 37th Annual Healthcare Conference to be held December 2 – 4, 2025. Bernard Coulie, M.D., Ph.D., President and Chief

(NASDAQ:LENZ),(TAI:1795.TW), SAN DIEGO and TAIPEI, Taiwan, Dec. 01, 2025 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSW Stock Code: 1795) today announced that Lotus has submitted a New Drug Application (NDA) to the Ministry of Food and Drug Safety (MFDS) for the review and approval of VIZZTM, for

(Other OTC:CYDY),(OTC US:CYDY), VANCOUVER, Washington, Dec. 01, 2025 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic triple-negative breast cancer (mTNBC) and colorectal cancer (mCRC), today announced that it has

(NASDAQ:HDSN), WOODCLIFF LAKE, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) — Hudson Technologies, Inc. (NASDAQ: HDSN) announced that its board of directors has approved an increase to the Company's share repurchase authorization. Hudson may now purchase up to $20 million in shares of its common stock during calendar year 2025, an increase from up to $10

(NASDAQ:DFDV), BOCA RATON, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) — DeFi Development Corp. (Nasdaq: DFDV) (the “Company”), the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced it has begun integrating and running the open block-building infrastructure provided by Harmonic across its Solana validator operations. Harmonic introduces competition

(NASDAQ:BDRX), December 1, 2025 Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce the enrolment of